Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients.

Nelson DR.

Liver Int. 2011 Jan;31 Suppl 1:53-7. doi: 10.1111/j.1478-3231.2010.02391.x. Review.

PMID:
21205138
2.

The role of triple therapy in HCV genotype 1-experienced patients.

Fried MW.

Liver Int. 2011 Jan;31 Suppl 1:58-61. doi: 10.1111/j.1478-3231.2010.02410.x.

PMID:
21205139
3.

Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?

Pascale A, Serfaty L.

J Hepatol. 2013 Feb;58(2):391-4. doi: 10.1016/j.jhep.2012.09.023. Epub 2012 Oct 9.

4.

Protease inhibitors: silver bullets for chronic hepatitis C infection?

Alkhouri N, Zein NN.

Cleve Clin J Med. 2012 Mar;79(3):213-22. doi: 10.3949/ccjm.79a.11082. Review.

5.

Hepatitis C drug development at a crossroads.

Nelson DR.

Hepatology. 2009 Oct;50(4):997-9. doi: 10.1002/hep.23208. No abstract available.

PMID:
19787813
6.

Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF).

Italian Association for the Study of the Liver (AISF), Coco B, Caraceni P, Aghemo A, Bitetto D, Bruno R, Ciancio A, Marzioni M, Petta S, Rendina M, Valenti L; Review Board:.

Dig Liver Dis. 2014 Jan;46(1):18-24. doi: 10.1016/j.dld.2013.08.243. Epub 2013 Oct 9. Review.

7.

New direct-acting antivirals' combination for the treatment of chronic hepatitis C.

Asselah T, Marcellin P.

Liver Int. 2011 Jan;31 Suppl 1:68-77. doi: 10.1111/j.1478-3231.2010.02411.x. Review.

PMID:
21205141
8.

An update on the management of hepatitis C: guidelines for protease inhibitor-based triple therapy from the Latin American Association for the Study of the Liver.

Chávez-Tapia NC, Ridruejo E, Alves de Mattos A, Bessone F, Daruich J, Sánchez-Ávila JF, Cheinquer H, Zapata R, Uribe M, Bosques-Padilla F, Gadano A, Sosa A, Dávalos-Moscol M, Marroni C, Muñoz-Espinoza L, Castro-Narro G, Paraná R, Méndez-Sánchez N; Latin American Association for the Study of the Liver.

Ann Hepatol. 2013 Mar-Apr;12 Suppl 2:s3-35.

9.

New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.

Dusheiko G, Wedemeyer H.

Gut. 2012 Dec;61(12):1647-52. doi: 10.1136/gutjnl-2012-302910. Epub 2012 Aug 30. No abstract available.

PMID:
22936671
10.

[Treatment of chronic hepatitis viral C: new associations].

Ouzan D.

Presse Med. 2013 Jun;42(6 Pt 1):977-82. doi: 10.1016/j.lpm.2012.06.019. Epub 2012 Sep 27. French.

PMID:
23021659
11.

Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.

Wyles DL, Gutierrez JA.

J Viral Hepat. 2014 Apr;21(4):229-40. doi: 10.1111/jvh.12230. Review.

PMID:
24597691
12.

A new era in the treatment of chronic hepatitis C infection.

Jothimani D, Chandy GM, Conjeevaram H.

Indian J Gastroenterol. 2013 Mar;32(2):71-9. doi: 10.1007/s12664-012-0254-5. Epub 2012 Sep 28. Review.

PMID:
23054947
13.

Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection.

Bock JA, Fairley KJ, Smith RE, Maeng DD, Pitcavage JM, Inverso NA, Williams MS.

Public Health Genomics. 2014;17(5-6):306-19. doi: 10.1159/000365939. Epub 2014 Sep 18.

14.

Prompt arrival of antivirals against hepatitis C for HIV patients.

Barreiro P, Vispo E.

AIDS Rev. 2010 Oct-Dec;12(4):242-3. No abstract available.

PMID:
21344779
15.

HCV NS5A inhibitors in development.

Suk-Fong Lok A.

Clin Liver Dis. 2013 Feb;17(1):111-21. doi: 10.1016/j.cld.2012.09.006. Review.

PMID:
23177287
16.

IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy.

Ioniţă-Radu F, Raşcanu A, Cheiab B.

Rom J Intern Med. 2011;49(2):99-104. Review.

PMID:
22303600
17.

[Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].

Hunyady B, Gervain J, Horváth G, Makara M, Pár A, Szalay F, Telegdy L, Tornai I.

Orv Hetil. 2014 Mar;155 Suppl:3-24. doi: 10.1556/OH.2013.29893. Hungarian.

PMID:
24631886
18.

[Treatment of hepatitis C: current status and perspectives].

Pol S, Corouge M.

Rev Prat. 2014 May;64(5):605-12. French.

PMID:
24923038
19.

Antiviral strategies in hepatitis C virus infection.

Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM.

J Hepatol. 2012;56 Suppl 1:S88-100. doi: 10.1016/S0168-8278(12)60010-5. Review.

PMID:
22300469
20.

[Hepatitis C virus: 25 years-old, the end?].

Pol S.

Med Sci (Paris). 2013 Nov;29(11):998-1003. doi: 10.1051/medsci/20132911016. Epub 2013 Nov 20. Review. French.

Supplemental Content

Support Center